Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Darifenacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 3/20 | 1.00 |
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 5/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 5/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 3/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | KCNE1 | P15382 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | HRH2 | P25021 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | KCNQ1 | P51787 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Darifenacin SCHEMBL31257801 | 1.00 | CHRM5 (1.00) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL2774455 | 1.00 | CHRM5 (1.00) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL56574 | 1.00 | CHRM5 (1.00) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL1023445 | 0.99 | CHRM5 (0.98) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL3662174 | 0.99 | CHRM5 (0.98) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL1318587 | 0.99 | CHRM5 (0.98) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL138745 | 0.99 | CHRM5 (0.98) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL5085916 | 0.99 | CHRM5 (0.98) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL453486 | 0.99 | CHRM5 (0.98) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL1973347 | 0.99 | CHRM5 (0.98) | CHRM5CHRM1CHRM4CHRM3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1034 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022257986-A1 | USE OF CYP450 INHIBITOR IN INHIBITING OR KILLING MITES AND TREATING DRY EYE SYNDROME | 广州岐微生物医药科技有限公司 | 2022-12-15 | — | — | WO | claimed |
| EP-2336124-B1 | Stable hydrate of a muscarinic receptor antagonist | NOVARTIS INT PHARM LTD (BM) | 2012-08-29 | — | — | EP | claimed |
| US-8058454-B2 | Method for preparing 1,3-disubstituted pyrrolidine compounds | MEDICHEM, S.A. (ES) | 2011-11-15 | — | — | US | claimed |
| WO-2011070419-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF DARIFENACIN HYDROBROMIDE | AUROBINDO PHARMA LIMITED (IN) | 2011-06-16 | — | — | WO | claimed |
| EP-1490357-B1 | Toluene solvate of darifenacin | NOVARTIS INT PHARM LTD (BM) | 2011-01-12 | — | — | EP | claimed |
| EP-2236509-A1 | Method for obtaining 1,3-difunctionalized pyrrolidine derivatives | Ragactives, S.L. (ES) | 2010-10-06 | — | — | EP | claimed |
| US-20100112061-A1 | Monophosphates as Mutual Prodrugs of Muscarinic Receptor Antagonists and Beta-Agonists for the Treatment of COPD And Chronic Bronchitis | GILEAD SCIENCES, INC. | 2010-05-06 | — | — | US | claimed |
| US-7696357-B2 | Stable hydrate of a muscarinic receptor antagonist | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2010-04-13 | — | — | US | claimed |
| EP-2160372-A1 | METHOD FOR DETERMINING ENANTIOMERIC PURITY OF DARIFENACIN AND INTERMEDIATES | Medichem, S.A. (ES) | 2010-03-10 | — | — | EP | claimed |
| US-20090306406-A1 | METHOD FOR PREPARING 1,3-DISUBSTITUTED PYRROLIDINE COMPOUNDS | MEDICHEM ,S.A. (ES) | 2009-12-10 | — | — | US | claimed |
| US-20050245597-A1 | Stable hydrate of a muscarinic receptor antagonist | DUNN PETER J | 2005-11-03 | — | — | US | claimed |
| WO-2005092341-A1 | COMBINATION THERAPY FOR LOWER URINARY TRACT SYMPTOMS | RANBAXY LABORATORIES LIMITED (IN) | 2005-10-06 | — | — | WO | claimed |
| US-6930188-B2 | Stable hydrate of a muscarinic receptor antagonist | NOVARTIS INTERNATIONAL PHARMACEUTICAL, LTD. (BE) | 2005-08-16 | — | — | US | claimed |
| EP-1490357-A1 | STABLE HYDRATE OF A MUSCARINIC RECEPTOR ANTAGONIST | Novartis International Pharmaceutical Ltd. (BM) | 2004-12-29 | — | — | EP | claimed |
| US-20030191176-A1 | Stable hydrate of a muscarinic receptor antagonist | PFIZER INC. | 2003-10-09 | — | — | US | claimed |
| WO-2003080599-A1 | STABLE HYDRATE OF A MUSCARINIC RECEPTOR ANTAGONIST | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2003-10-02 | — | — | WO | claimed |
| WO-1995019164-A1 | USE OF M3 MUSCARINIC ANTAGONISTS FOR THE TREATMENT OF MOTION SICKNESS | PFIZER LIMITED (GB) | 1995-07-20 | — | — | WO | claimed |
| EP-0388054-B1 | Pyrrolidine derivatives | PFIZER LTD (GB) | 1993-11-03 | — | — | EP | claimed |
| US-5096890-A | PYRROLIDINE DERIVATIVES | PFIZER INC. (US) | 1992-03-17 | — | — | US | claimed |
| EP-0388054-A1 | Pyrrolidine derivatives | Pfizer Limited (GB) | 1990-09-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191176-A1 | Stable hydrate of a muscarinic receptor antagonist | CHRM5, CHRM2, CHRM3 | CHRM3 3/4885CHRM2 2/4885CHRM5 1/4885 |
| US-20050245597-A1 | Stable hydrate of a muscarinic receptor antagonist | CHRM5, CHRM2, CHRM3 | CHRM3 3/4885CHRM2 2/4885CHRM5 1/4885 |
| US-20090306406-A1 | METHOD FOR PREPARING 1,3-DISUBSTITUTED PYRROLIDINE COMPOUNDS | OPRL1, OPRK1, OPRD1 | CHRM3 108/4885CHRM2 431/4885CHRM5 423/4885 |
| US-20100112061-A1 | Monophosphates as Mutual Prodrugs of Muscarinic Receptor Antagonists and Beta-Agonists for the Treatment of COPD And Chronic Bronchitis | ADRB1, ADRB2, CHRM3 | CHRM3 3/4885CHRM2 5/4885CHRM5 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.